Leiden

• Long-term efficacy, safety and tolerability of LNP023 in C3G or IC-MPGN Recruiting
  2023-509343-27-00 11 2019-10-28 C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
• SGM-LARRC: Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carc … Recruiting
  2024-510768-21-00 4 2019-10-16 Rectal cancer
• Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and Ad … Recruiting
  2024-512321-84-00 5 2019-10-02 Patients after HSCT suffering from new or reactivated CMV or EBV or Ad
• Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients Recruiting
  2023-507868-39-00 6 2019-05-03 ANCA Vasculitis
• Study in which all the patients take the same investigational drug with the aim of evaluate the long-term safety, tolerability, and efficacy … Recruiting
  2023-504520-26-00 5 2017-10-19 Duchenne Muscular Dystrophy (DMD)
• Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international r … Recruiting
  2024-516196-32-00 5 2017-01-01 breast cancer
• DRUP trial Recruiting
  2023-509152-33-00 4 2016-07-25 Advanced solid tumor
• Late immunity following single immunization with GA2 sporozoites (GACHA) Ended recruitment
  2025-524045-27-00 9 2026-03-11 Falciparum malaria
• A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou … Ended recruitment
  2025-522598-12-00 10 2025-12-17 Untreated Metastatic Pancreatic Ductal Adenocarcinoma
• Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended recruitment
  2025-521681-10-00 4 2025-10-02 Lung Cancer
• Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended recruitment
  2024-517356-35-00 4 2025-07-29 Moderately Active Rheumatoid Arthritis
• A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended recruitment
  2024-517143-31-00 4 2025-07-18 Autosomal Dominant Polycystic Kidney Disease
• A Study to Evaluate the Efficacy, Safety and Tolerability of ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA) Ended recruitment
  2023-510137-29-01 4 2025-04-09 Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L … Ended recruitment
  2022-501489-24-00 5 2025-03-28 First-line treatment of adult subjects with high-risk large B-cell lym
• A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended recruitment
  2024-514133-38-00 5 2025-03-19 Ocular Myasthenia Gravis
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND- … Ended recruitment
  2024-514047-28-00 5 2025-01-27 HIV-1 Infection
• Het effect van psilocybine op pijn bij fibromyalgiepatiënten: een multicenter trial Ended recruitment
  2024-516890-63-00 4 2025-01-21 Fibromyalgia
• An open-label study to collect safety and effectiveness information on long-term treatment with vamorolone in boys with Duchenne Muscular Dy … Ended recruitment
  2024-512828-12-00 6 2024-12-05 Duchenne Muscular Dystrophy
• Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment Ended recruitment
  2024-517467-23-00 5 2024-11-29 steroid sensitive idiopathic nephrotic syndrome
• A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative … Ended recruitment
  2024-511796-15-00 5 2024-10-16 Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
• A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladde … Ended recruitment
  2023-509460-19-00 9 2024-10-11 Muscle Invasive bladder cancer
• CIAO@TBI Ended recruitment
  2024-514488-24-02 4 2024-10-09 Traumatic Brain Injury
• Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point … Ended recruitment
  2024-511530-12-01 6 2024-10-01 Rheumatoid arthritis according to 2010 criteria

Showing 241–264 of 459 trials